{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:53:37Z","timestamp":1783140817362,"version":"3.54.6"},"reference-count":35,"publisher":"Oxford University Press (OUP)","funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Shorter prophylactic vaccine schedules may offer more rapid protection against Ebola in resource-limited settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This randomized, observer-blind, placebo-controlled, phase 2 trial conducted in 5 sub-Saharan African countries included people without human immunodeficiency virus (HIV) (PWOH, n = 249) and people with HIV (PWH, n = 250). Adult participants received 1 of 2 accelerated Ebola vaccine regimens (MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart [n = 79] or Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart [n = 322]) or saline\/placebo (n = 98). The primary endpoints were safety (adverse events [AEs]) and immunogenicity (Ebola virus [EBOV] glycoprotein\u2013specific binding antibody responses). Binding antibody responders were defined as participants with a &amp;gt;2.5-fold increase from baseline or the lower limit of quantification if negative at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean age was 33.4 years, 52% of participants were female, and among PWH, the median CD4+ cell count was 560.0 (interquartile range, 418.0\u2013752.0) cells\/\u03bcL. AEs were generally mild\/moderate with no vaccine-related serious AEs or remarkable safety profile differences by HIV status. At 21 days post\u2013dose 2, EBOV glycoprotein\u2013specific binding antibody response rates in vaccine recipients were 99% for the 14-day regimen (geometric mean concentrations [GMCs]: 5168 enzyme-linked immunosorbent assay units [EU]\/mL in PWOH; 2509\u2005EU\/mL in PWH) and 98% for the 28-day regimen (GMCs: 6037\u2005EU\/mL in PWOH; 2939\u2005EU\/mL in PWH). At 12 months post\u2013dose 2, GMCs in PWOH and PWH were 635 and 514\u2005EU\/mL, respectively, for the 14-day regimen and 331 and 360\u2005EU\/mL, respectively, for the 28-day regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Accelerated 14- and 28-day Ebola vaccine regimens were safe and immunogenic in PWOH and PWH in Africa.<\/jats:p>\n                  <jats:p>Clinical Trials Registration.\u2003NCT02598388.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae215","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:14:42Z","timestamp":1713694482000},"source":"Crossref","is-referenced-by-count":5,"title":["Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without Human Immunodeficiency Virus in Africa"],"prefix":"10.1093","author":[{"given":"Betty","family":"Mwesigwa","sequence":"first","affiliation":[{"name":"Makerere University Walter Reed Project , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Sawe","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"HJF Medical Research International , Kisumu , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Oyieko","sequence":"additional","affiliation":[{"name":"HJF Medical Research International , Kisumu , Kenya"},{"name":"Kenya Medical Research Institute\/US Army Medical Research Directorate\u2013Africa , Kisumu , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Mwakisisile","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research\u2013Mbeya Medical Research Center , Mbeya , Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Viegas","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade , Maputo , Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon Akindiran","family":"Akintunde","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"HJF Medical Research International , Abuja , Nigeria"},{"name":"US Army Medical Research Directorate\u2013Africa , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josphat","family":"Kosgei","sequence":"additional","affiliation":[{"name":"HJF Medical Research International , Kisumu , Kenya"},{"name":"Kenya Medical Research Institute\/US Army Medical Research Directorate\u2013Africa , Kisumu , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afoke","family":"Kokogho","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"HJF Medical Research International , Abuja , Nigeria"},{"name":"US Army Medical Research Directorate\u2013Africa , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyanda","family":"Ntinginya","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research\u2013Mbeya Medical Research Center , Mbeya , Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilesh","family":"Jani","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Sa\u00fade , Maputo , Mozambique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Shukarev","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W","family":"Hooper","sequence":"additional","affiliation":[{"name":"Virology Division, US Army Medical Research Institute of Infectious Diseases , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Kwilas","sequence":"additional","affiliation":[{"name":"Virology Division, US Army Medical Research Institute of Infectious Diseases , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A","family":"Ward","sequence":"additional","affiliation":[{"name":"US Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Rusnak","sequence":"additional","affiliation":[{"name":"Contract Support for DOD JPEO-CBRND, JPM CBRN Medical , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callie","family":"Bounds","sequence":"additional","affiliation":[{"name":"US Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Overman","sequence":"additional","affiliation":[{"name":"US Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Badorrek","sequence":"additional","affiliation":[{"name":"Contract Support for DOD JPEO-CBRND, JPM CBRN Medical , Fort Detrick, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh Anne","family":"Eller","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Eller","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S","family":"Polyak","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Moodley","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi L","family":"Tran","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret C","family":"Costanzo","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Leggat","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Paquin-Proulx","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy","family":"Naluyima","sequence":"additional","affiliation":[{"name":"Makerere University Walter Reed Project , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickson Nkafu","family":"Anumendem","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auguste","family":"Gaddah","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"McLean","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kibuuka","sequence":"additional","affiliation":[{"name":"Makerere University Walter Reed Project , Kampala , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin L","family":"Robb","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Ake","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2024082812161754000_ciae215-B1","author":"Centers for Disease Control and Prevention"},{"key":"2024082812161754000_ciae215-B2","author":"World Health Organization"},{"key":"2024082812161754000_ciae215-B3","author":"European Medicines Agency"},{"key":"2024082812161754000_ciae215-B4","author":"European Medicines Agency"},{"key":"2024082812161754000_ciae215-B5","author":"World Health Organization"},{"key":"2024082812161754000_ciae215-B6","author":"World Health Organization"},{"key":"2024082812161754000_ciae215-B7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024082812161754000_ciae215-B8","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"key":"2024082812161754000_ciae215-B9","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"2024082812161754000_ciae215-B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024082812161754000_ciae215-B11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024082812161754000_ciae215-B12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for Zaire Ebola virus disease","volume":"387","author":"PREVAC Study Team","year":"2022","journal-title":"N Engl J Med"},{"key":"2024082812161754000_ciae215-B13","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017","volume":"6","author":"GBD 2017 HIV Collaborators","year":"2019","journal-title":"Lancet HIV"},{"key":"2024082812161754000_ciae215-B14","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/S2352-3018(21)00051-5","article-title":"Subnational mapping of HIV incidence and mortality among individuals aged 15\u201349 years in sub-Saharan Africa, 2000\u201318: a modelling study","volume":"8","author":"Sartorius","year":"2021","journal-title":"Lancet HIV"},{"key":"2024082812161754000_ciae215-B15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1473-3099(12)70243-8","article-title":"Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1","volume":"12","author":"Whitaker","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2024082812161754000_ciae215-B16","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","article-title":"Hepatitis B virus coinfection in human immunodeficiency virus\u2013infected patients: a review","volume":"20","author":"Sun","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024082812161754000_ciae215-B17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2008.10.040","article-title":"Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients","volume":"27","author":"Cruciani","year":"2009","journal-title":"Vaccine"},{"key":"2024082812161754000_ciae215-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/QAI.0000000000000845","article-title":"CD4\/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients","volume":"71","author":"Avelino-Silva","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024082812161754000_ciae215-B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2172-13-49","article-title":"Responses to pandemic ASO3-adjuvanted A\/California\/07\/09 H1N1 influenza vaccine in human immunodeficiency virus\u2013infected individuals","volume":"13","author":"Kelly","year":"2012","journal-title":"BMC Immunol"},{"key":"2024082812161754000_ciae215-B20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2024082812161754000_ciae215-B21","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara\u2013vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"2024082812161754000_ciae215-B22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia Ankara\u2013vectored Ebola vaccines: a randomized, controlled phase 1 study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J Infect Dis"},{"key":"2024082812161754000_ciae215-B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"2024082812161754000_ciae215-B24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara\u2013vectored Ebola vaccines at 1 year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA"},{"key":"2024082812161754000_ciae215-B25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12\u2013month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"2024082812161754000_ciae215-B26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines12050497","article-title":"Safety and immunogenicity of an accelerated Ebola vaccination schedule in people with and without human immunodeficiency virus: a randomized clinical trial","volume":"12","author":"Ake JA, Paolino K, Hutter JN, et al.","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2024082812161754000_ciae215-B27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jviromet.2018.02.018","article-title":"Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay","volume":"255","author":"Logue","year":"2018","journal-title":"J Virol Methods"},{"key":"2024082812161754000_ciae215-B28","doi-asserted-by":"crossref","first-page":"682120","DOI":"10.3389\/fimmu.2021.682120","article-title":"Associations between antibody Fc-mediated effector functions and long-term sequelae in Ebola virus survivors","volume":"12","author":"Paquin-Proulx","year":"2021","journal-title":"Front Immunol"},{"key":"2024082812161754000_ciae215-B29","doi-asserted-by":"crossref","first-page":"45552","DOI":"10.1038\/srep45552","article-title":"Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"2024082812161754000_ciae215-B30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"2024082812161754000_ciae215-B31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"2024082812161754000_ciae215-B32","doi-asserted-by":"crossref","first-page":"112402","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep"},{"key":"2024082812161754000_ciae215-B33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"2024082812161754000_ciae215-B34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2024082812161754000_ciae215-B35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/v15020575","article-title":"SARS-CoV-2 vaccine-induced T-cell response after 3 doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 COVAXHIV Study)","volume":"15","author":"Alexandrova","year":"2023","journal-title":"Viruses"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae215\/58941318\/ciae215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae215\/58941318\/ciae215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:37:30Z","timestamp":1724855850000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciae215\/7657723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae215","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"article-number":"ciae215"}}